Among them was a promising ­candidate, remdesivir, which had achieved some success against Ebola and two coronaviruses. Fortunately that hasn’t stopped a trial with selected NHS patients in hospital suffering from Covid-19. They’ll be given remdesivir after a very early study found it shortened the time to recovery by about four days, reports Zosia Kmietowicz in the BMJ. Stephen Griffin, associate professor at Leeds School of Medicine, has said that remdesivir is the most promising antiviral drug in current trials among Covid-19 patients. “Rolling out ­remdesivir via the EAMS will likely mean that the most severe Covid-19 patients will receive it first,” he says.

Source: Daily Mirror July 06, 2020 15:44 UTC